FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4372332075> ?p ?o ?g. }

• W4372332075 endingPage "e011193" @default.
• W4372332075 startingPage "e011193" @default.
• W4372332075 abstract "Delivering preventive chemotherapy through mass drug administration (MDA) is a central approach in controlling or eliminating several neglected tropical diseases (NTDs). Treatment coverage, a primary indicator of MDA performance, can be measured through routinely reported programmatic data or population-based coverage evaluation surveys. Reported coverage is often the easiest and least expensive way to estimate coverage; however, it is prone to inaccuracies due to errors in data compilation and imprecise denominators, and in some cases measures treatments offered as opposed to treatments swallowed.Analyses presented here aimed to understand (1) how often coverage calculated using routinely reported data and survey data would lead programme managers to make the same programmatic decisions; (2) the magnitude and direction of the difference between these two estimates, and (3) whether there is meaningful variation by region, age group or country.We analysed and compared reported and surveyed treatment coverage data from 214 MDAs implemented between 2008 and 2017 in 15 countries in Africa, Asia and the Caribbean. Routinely reported treatment coverage was compiled using data reported by national NTD programmes to donors, either directly or via NTD implementing partners, following the implementation of a district-level MDA campaign; coverage was calculated by dividing the number of individuals treated by a population value, which is typically based on national census projections and occasionally community registers. Surveyed treatment coverage came from post-MDA community-based coverage evaluation surveys, which were conducted as per standardised WHO recommended methodology.Coverage estimates using routine reporting and surveys gave the same result in terms of whether the minimum coverage threshold was reached in 72% of the MDAs surveyed in the Africa region and in 52% in the Asia region. The reported coverage value was within ±10 percentage points of the surveyed coverage value in 58/124 of the surveyed MDAs in the Africa region and 19/77 in the Asia region. Concordance between routinely reported and surveyed coverage estimates was 64% for the total population and 72% for school-age children. The study data showed variation across countries in the number of surveys conducted as well as the frequency with which there was concordance between the two coverage estimates.Programme managers must grapple with making decisions based on imperfect information, balancing needs for accuracy with cost and available capacity. The study shows that for many of the MDAs surveyed, based on the concordance with respect to reaching the minimum coverage thresholds, the routinely reported data were accurate enough to make programmatic decisions. Where coverage surveys do show a need to improve accuracy of routinely reported results, NTD programme managers should use various tools and approaches to strengthen data quality in order to use data for decision-making to achieve NTD control and elimination goals." @default.
• W4372332075 created "2023-05-07" @default.
• W4372332075 creator A5000970346 @default.
• W4372332075 creator A5007248125 @default.
• W4372332075 creator A5010243936 @default.
• W4372332075 creator A5015632692 @default.
• W4372332075 creator A5016354363 @default.
• W4372332075 creator A5018974954 @default.
• W4372332075 creator A5023222900 @default.
• W4372332075 creator A5029605009 @default.
• W4372332075 creator A5029735481 @default.
• W4372332075 creator A5030716775 @default.
• W4372332075 creator A5033233217 @default.
• W4372332075 creator A5033487717 @default.
• W4372332075 creator A5034582350 @default.
• W4372332075 creator A5034774766 @default.
• W4372332075 creator A5036265899 @default.
• W4372332075 creator A5040619293 @default.
• W4372332075 creator A5045039770 @default.
• W4372332075 creator A5045627650 @default.
• W4372332075 creator A5047008893 @default.
• W4372332075 creator A5053518757 @default.
• W4372332075 creator A5053765071 @default.
• W4372332075 creator A5054857534 @default.
• W4372332075 creator A5055290629 @default.
• W4372332075 creator A5061831461 @default.
• W4372332075 creator A5064557027 @default.
• W4372332075 creator A5065553488 @default.
• W4372332075 creator A5065658064 @default.
• W4372332075 creator A5078459010 @default.
• W4372332075 creator A5080670870 @default.
• W4372332075 creator A5082202442 @default.
• W4372332075 creator A5085270643 @default.
• W4372332075 creator A5087315014 @default.
• W4372332075 creator A5089322942 @default.
• W4372332075 creator A5091795122 @default.
• W4372332075 date "2023-05-01" @default.
• W4372332075 modified "2023-10-06" @default.
• W4372332075 title "How well do coverage surveys and programmatically reported mass drug administration coverage match? Results from 214 mass drug administration campaigns in 15 countries, 2008–2017" @default.
• W4372332075 cites W1968683367 @default.
• W4372332075 cites W1980276147 @default.
• W4372332075 cites W2004520320 @default.
• W4372332075 cites W2007516286 @default.
• W4372332075 cites W2012190283 @default.
• W4372332075 cites W2028931700 @default.
• W4372332075 cites W2059637455 @default.
• W4372332075 cites W2087314245 @default.
• W4372332075 cites W2103356588 @default.
• W4372332075 cites W2104372971 @default.
• W4372332075 cites W2112537590 @default.
• W4372332075 cites W2113300647 @default.
• W4372332075 cites W2113384461 @default.
• W4372332075 cites W2118256986 @default.
• W4372332075 cites W2128453845 @default.
• W4372332075 cites W2143492826 @default.
• W4372332075 cites W2151021155 @default.
• W4372332075 cites W2164642717 @default.
• W4372332075 cites W2238272448 @default.
• W4372332075 cites W2283809401 @default.
• W4372332075 cites W2313339984 @default.
• W4372332075 cites W2331464746 @default.
• W4372332075 cites W2333571867 @default.
• W4372332075 cites W234342802 @default.
• W4372332075 cites W2601511948 @default.
• W4372332075 cites W2771351094 @default.
• W4372332075 cites W2789231654 @default.
• W4372332075 cites W2969097329 @default.
• W4372332075 cites W2996716285 @default.
• W4372332075 cites W4229371057 @default.
• W4372332075 cites W597933164 @default.
• W4372332075 doi "https://doi.org/10.1136/bmjgh-2022-011193" @default.
• W4372332075 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37142297" @default.
• W4372332075 hasPublicationYear "2023" @default.
• W4372332075 type Work @default.
• W4372332075 citedByCount "0" @default.
• W4372332075 crossrefType "journal-article" @default.
• W4372332075 hasAuthorship W4372332075A5000970346 @default.
• W4372332075 hasAuthorship W4372332075A5007248125 @default.
• W4372332075 hasAuthorship W4372332075A5010243936 @default.
• W4372332075 hasAuthorship W4372332075A5015632692 @default.
• W4372332075 hasAuthorship W4372332075A5016354363 @default.
• W4372332075 hasAuthorship W4372332075A5018974954 @default.
• W4372332075 hasAuthorship W4372332075A5023222900 @default.
• W4372332075 hasAuthorship W4372332075A5029605009 @default.
• W4372332075 hasAuthorship W4372332075A5029735481 @default.
• W4372332075 hasAuthorship W4372332075A5030716775 @default.
• W4372332075 hasAuthorship W4372332075A5033233217 @default.
• W4372332075 hasAuthorship W4372332075A5033487717 @default.
• W4372332075 hasAuthorship W4372332075A5034582350 @default.
• W4372332075 hasAuthorship W4372332075A5034774766 @default.
• W4372332075 hasAuthorship W4372332075A5036265899 @default.
• W4372332075 hasAuthorship W4372332075A5040619293 @default.
• W4372332075 hasAuthorship W4372332075A5045039770 @default.
• W4372332075 hasAuthorship W4372332075A5045627650 @default.
• W4372332075 hasAuthorship W4372332075A5047008893 @default.
• W4372332075 hasAuthorship W4372332075A5053518757 @default.
• W4372332075 hasAuthorship W4372332075A5053765071 @default.
• W4372332075 hasAuthorship W4372332075A5054857534 @default.

• next